Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy


Altay H., Colkesen Y.

ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, cilt.13, ss.100-104, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 13 Konu: 1
  • Basım Tarihi: 2013
  • Doi Numarası: 10.2174/1871530311313010012
  • Dergi Adı: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS
  • Sayfa Sayıları: ss.100-104

Özet

Heart failure (HF) is a clinical syndrome featuring cardiac pump failure along with signs and symptoms arising from salt and water retention mediated by activated renin-angiotensin-aldosterone system (RAAS). In addition to this cardiorenal perspective, HF is accompanied by a systemic illness, especially in advanced stages characterized by oxidative stress in various tissues, causing damage to soft tissue and bone. Secondary hyperparathyroidism (SHPT) which is also considered to contribute this systemic illness is therefore prominent in advanced HF. SHPT in HF occurs as a result of RAAS activation, prominent hyperaldosteronism, loop diuretic usage and decreased calcitriol level, all of which results in calcium excretion. We review the evidence that high parathyroid hormone (PTH) is associated with advanced HF, as well as evidence that it's associated with HF with preserved ejection fraction (HFPEF).